EA201190092A1 - Композиции с отсроченным высвобождением для перорального применения, содержащие аморфный бардоксолон метил (cddo-me) - Google Patents

Композиции с отсроченным высвобождением для перорального применения, содержащие аморфный бардоксолон метил (cddo-me)

Info

Publication number
EA201190092A1
EA201190092A1 EA201190092A EA201190092A EA201190092A1 EA 201190092 A1 EA201190092 A1 EA 201190092A1 EA 201190092 A EA201190092 A EA 201190092A EA 201190092 A EA201190092 A EA 201190092A EA 201190092 A1 EA201190092 A1 EA 201190092A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
methyl
bardoxolon
cddo
containing amorphous
Prior art date
Application number
EA201190092A
Other languages
English (en)
Other versions
EA023652B1 (ru
Inventor
Цзян Чжан
Колин Дж. Мейер
Original Assignee
Реата Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42335073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201190092(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Реата Фармасьютикалз, Инк. filed Critical Реата Фармасьютикалз, Инк.
Publication of EA201190092A1 publication Critical patent/EA201190092A1/ru
Publication of EA023652B1 publication Critical patent/EA023652B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Abstract

Согласно настоящему изобретению предложены фармацевтические составы, обеспечивающие необходимое низкое значение C, среди других свойств, при этом указанные составы содержат частицы аморфного бардоксолон метила, либо в чистой форме, либо в форме твердой дисперсии, в смеси с частицами гидрофильного связующего агента. Такие составы имеют преимущество в виде высокой пероральной биодоступности по сравнению с составами на основе кристаллической формы бардоксолон метила.
EA201190092A 2009-02-13 2010-02-12 Композиции с отсроченным высвобождением для перорального применения, содержащие аморфный бардоксолон метил (cddo-me) EA023652B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15260809P 2009-02-13 2009-02-13
PCT/US2010/024127 WO2010093944A2 (en) 2009-02-13 2010-02-12 Delayed release, oral dosage compositions that contain amorphous cddo-me

Publications (2)

Publication Number Publication Date
EA201190092A1 true EA201190092A1 (ru) 2012-02-28
EA023652B1 EA023652B1 (ru) 2016-06-30

Family

ID=42335073

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201190092A EA023652B1 (ru) 2009-02-13 2010-02-12 Композиции с отсроченным высвобождением для перорального применения, содержащие аморфный бардоксолон метил (cddo-me)

Country Status (29)

Country Link
US (2) US8747901B2 (ru)
EP (2) EP2395979B1 (ru)
JP (1) JP5775464B2 (ru)
KR (2) KR101483203B1 (ru)
CN (2) CN102387789A (ru)
AU (1) AU2010213594B2 (ru)
BR (1) BRPI1008023B8 (ru)
CA (1) CA2752048C (ru)
CO (1) CO6361904A2 (ru)
CY (2) CY1119595T1 (ru)
DK (2) DK2395979T3 (ru)
EA (1) EA023652B1 (ru)
ES (2) ES2731601T3 (ru)
HK (1) HK1220130A1 (ru)
HR (2) HRP20171639T1 (ru)
HU (2) HUE044005T2 (ru)
IL (1) IL214258A (ru)
LT (2) LT3254675T (ru)
MX (1) MX2011008344A (ru)
MY (1) MY173715A (ru)
NO (1) NO2395979T3 (ru)
NZ (1) NZ594488A (ru)
PL (2) PL2395979T3 (ru)
PT (2) PT2395979T (ru)
SG (1) SG173601A1 (ru)
SI (2) SI2395979T1 (ru)
TR (1) TR201909743T4 (ru)
WO (1) WO2010093944A2 (ru)
ZA (1) ZA201105630B (ru)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
AU2009203941B2 (en) 2008-01-11 2015-03-12 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids and methods of use in the treatment of disease
BRPI0911422B8 (pt) 2008-04-18 2021-05-25 Reata Pharmaceuticals Inc compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos
WO2009146218A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
SI2276493T1 (sl) 2008-04-18 2019-04-30 Reata Pharmaceuticals, Inc. Antioksidantni modulatorji vnetja: derivati oleanolne kisline z amino in drugimi modifikacijami pri C-17
TWI442925B (zh) 2008-04-18 2014-07-01 Reata Pharmaceuticals Inc 抗氧化性發炎調節劑：ｃ－環飽和之齊墩果酸衍生物
WO2010011782A1 (en) 2008-07-22 2010-01-28 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
AU2010213594B2 (en) 2009-02-13 2013-11-14 Reata Pharmaceuticals Holdings, LLC Delayed release, oral dosage compositions that contain amorphous CDDO-Me
SI2558105T1 (sl) 2010-04-12 2020-02-28 Reata Pharmaceuticals, Inc. Bardoksolon metil za zdravljenje debelosti
ME02973B (me) 2010-12-17 2018-07-20 Reata Pharmaceuticals Inc Pirazolil i pirimidinil triciklični enoni kao antioksidantni modulatori inflamacije
EA026847B1 (ru) 2011-03-11 2017-05-31 Рита Фармасьютикалз, Инк. C4-монометилтритерпеноидные производные и способы их применения
CN103156861B (zh) * 2011-12-08 2015-11-25 陈丽梅 齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
HUE053113T2 (hu) 2012-04-27 2021-06-28 Reata Pharmaceuticals Inc Bardoxolon-metil 2,2-difluorpropionamid-származéka, annak gyógyszerkészítményei és polimorfjai bizonyos betegségek kezelésében történõ alkalmazásra
US8981144B2 (en) 2012-05-08 2015-03-17 Trustees Of Dartmouth College Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
ES2731758T3 (es) 2012-09-10 2019-11-18 Reata Pharmaceuticals Inc Derivados de alcanodiil y alquenodiil de c17 del ácido oleanólico y métodos de uso de los mismos
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
AR096046A1 (es) 2013-04-24 2015-12-02 Abbvie Inc Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso
BR112016003454B1 (pt) 2013-08-23 2023-02-14 Reata Pharmaceuticals, Inc. Uso de composto de metil bardoxolona
US20170333450A1 (en) 2014-10-31 2017-11-23 The Regents Of The University Of California Compositions and methods for treating hiv-associated cognitive dysfunction
WO2016130927A1 (en) 2015-02-12 2016-08-18 Reata Pharmaceuticals, Inc. Imidazolyl tricyclic enones as antioxidant iflammation modulators
CN108290922B (zh) 2015-09-23 2021-12-07 里亚塔医药公司 用于抑制il-17和其它用途的c4-改性的齐墩果酸衍生物
WO2018089539A1 (en) 2016-11-08 2018-05-17 Reata Pharmaceuticals, Inc. Methods of treating alport syndrome using bardoxolone methyl or analogs thereof
PE20191490A1 (es) 2016-12-16 2019-10-21 Reata Pharmaceuticals Inc DERIVADOS DE LA PIRIMIDIN ENONA TRICICLICA PARA LA INHIBICION DE RORy Y OTROS USOS
WO2019014412A1 (en) 2017-07-13 2019-01-17 Pliva Hrvatska D.O.O. NOVEL CRYSTALLINE POLYMORPHIC FORMS OF METHYL BARDOXOLONE
US11708463B2 (en) 2018-04-06 2023-07-25 Capsugel Belgium Nv Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)]
TW202038918A (zh) 2018-11-27 2020-11-01 日商協和麒麟股份有限公司 醫藥組合物
KR20230022164A (ko) 2020-05-09 2023-02-14 리아타 파마슈티컬즈 홀딩스, 엘엘씨 바독솔론 메틸 또는 이의 유사체를 사용하여 covid-19를 치료하는 방법
WO2022126129A1 (en) 2020-12-11 2022-06-16 Reata Pharmaceuticals, Inc. Synthetic triterpenoids for use in therapy
CN114558019A (zh) * 2022-03-26 2022-05-31 中国科学院昆明动物研究所 一种Rab13基因抑制剂及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
JP2008110962A (ja) * 2006-08-02 2008-05-15 Santen Pharmaceut Co Ltd Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤
JP4315182B2 (ja) * 2006-10-30 2009-08-19 ミツミ電機株式会社 カメラモジュール
JP2008247898A (ja) 2007-03-08 2008-10-16 Santen Pharmaceut Co Ltd トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
AU2009203941B2 (en) 2008-01-11 2015-03-12 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids and methods of use in the treatment of disease
AU2010213594B2 (en) * 2009-02-13 2013-11-14 Reata Pharmaceuticals Holdings, LLC Delayed release, oral dosage compositions that contain amorphous CDDO-Me

Also Published As

Publication number Publication date
BRPI1008023B8 (pt) 2023-04-11
ES2646816T3 (es) 2017-12-18
JP2012518008A (ja) 2012-08-09
EP2395979B1 (en) 2017-08-23
CO6361904A2 (es) 2012-01-20
CA2752048C (en) 2014-11-25
KR20110118721A (ko) 2011-10-31
HUE044005T2 (hu) 2019-09-30
CN105232471A (zh) 2016-01-13
BRPI1008023A2 (pt) 2016-03-15
CY1122066T1 (el) 2020-11-25
AU2010213594B2 (en) 2013-11-14
ZA201105630B (en) 2012-04-25
US20140235711A1 (en) 2014-08-21
US9155721B2 (en) 2015-10-13
HRP20171639T1 (hr) 2017-12-15
LT3254675T (lt) 2019-06-25
US8747901B2 (en) 2014-06-10
NZ594488A (en) 2013-10-25
PL3254675T3 (pl) 2019-09-30
EA023652B1 (ru) 2016-06-30
MY173715A (en) 2020-02-18
EP3254675A1 (en) 2017-12-13
TR201909743T4 (tr) 2019-07-22
SG173601A1 (en) 2011-09-29
WO2010093944A2 (en) 2010-08-19
AU2010213594A1 (en) 2011-08-18
WO2010093944A3 (en) 2011-08-11
CA2752048A1 (en) 2010-08-19
BRPI1008023B1 (pt) 2019-12-31
NO2395979T3 (ru) 2018-01-20
PT3254675T (pt) 2019-06-14
PT2395979T (pt) 2017-11-16
HRP20191092T1 (hr) 2019-11-29
CY1119595T1 (el) 2018-03-07
DK3254675T3 (da) 2019-06-24
SI3254675T1 (sl) 2019-08-30
PL2395979T3 (pl) 2018-02-28
MX2011008344A (es) 2011-09-29
DK2395979T3 (da) 2017-11-27
JP5775464B2 (ja) 2015-09-09
KR101483203B1 (ko) 2015-01-15
KR20140016441A (ko) 2014-02-07
EP2395979A2 (en) 2011-12-21
HK1220130A1 (zh) 2017-04-28
ES2731601T3 (es) 2019-11-18
HUE035013T2 (en) 2018-05-02
SI2395979T1 (sl) 2017-12-29
EP3254675B1 (en) 2019-05-15
LT2395979T (lt) 2017-12-11
US20120022156A1 (en) 2012-01-26
IL214258A (en) 2017-06-29
CN102387789A (zh) 2012-03-21
IL214258A0 (en) 2011-09-27

Similar Documents

Publication Publication Date Title
EA201190092A1 (ru) Композиции с отсроченным высвобождением для перорального применения, содержащие аморфный бардоксолон метил (cddo-me)
JOP20180102B1 (ar) مركب صيدلاني
CY1121233T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα καtα του υποδοχεα iντερλευκinης-4(ιl-4r)
WO2011107186A3 (de) Verbindungen für elektronische vorrichtungen
EA201290482A1 (ru) Стабильные составы для лиофилизации терапевтических частиц
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
WO2012021715A3 (en) Stable formulations of linaclotide
WO2009147075A3 (en) Pharmaceutical compositions containing a crystalline form of posaconazole
WO2010149169A3 (en) Controlled release formulations
CA2757418C (en) Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
WO2011098582A3 (en) Novel crystalline forms of ivabradine hydrochloride
WO2011157720A3 (en) Ivabradine-containing pharmaceutical composition with modified release
WO2010055082A3 (en) New crystal form of sunitinib malate
WO2009135646A3 (en) Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale
WO2012075362A3 (en) Chemokine cxcr4 receptor modulators and used related thereto
WO2011146583A3 (en) Nanoparticulate cinacalcet formulations
WO2010049449A3 (en) Novel salts of sunitinib
MX2011007267A (es) Composiciones farmaceuticas que comprenden derivados de 2-oxo-1-pirrolidina.
MX2011007451A (es) Composiciones farmaceuticas que comprenden derivados de 2-oxo-1 pirrolidina.
WO2009115084A3 (de) Pyrrolopyrimidin-derivate und deren verwendungen
WO2010006904A3 (en) Crystalline forms of rabeprazole sodium
WO2012029074A3 (en) Pharmaceutical compositions of linezolid
MX2013012773A (es) Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas.
EP2568810A4 (en) COMPOSITIONS OF DARUNAVIR
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM